What's in Universidad de Guanajuato's pipeline?

Universidad de Guanajuato has 8 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Universidad de Guanajuato's portfolio?

Top competitors by shared drug class: Federal University of Minas Gerais, HaEmek Medical Center, Israel, Instituto de Investigacion Sanitaria La Fe, Johns Hopkins University, Norwegian University of Science and Technology.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidad-de-guanajuato.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universidad de Guanajuato — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universidad de Guanajuato pipeline: 3 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Glargine and Lispro insulin	Glargine and Lispro insulin	marketed
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway	Diabetes
Chlorhexidine gluconate at 0.125%	Chlorhexidine gluconate at 0.125%	marketed
Chlorhexidine gluconate at 0.12%	Chlorhexidine gluconate at 0.12%	phase 3	Antimicrobial agent / Antiseptic	Bacterial cell membrane	Infectious Disease / Oral Health
Chlorhexidine gluconate at 2%	Chlorhexidine gluconate at 2%	phase 3	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins	Infectious Disease / Antisepsis
Antiseptic substantivity	Antiseptic substantivity	phase 3			Oral Health / Dentistry
chlorhexidine in isopropyl alcohol	chlorhexidine in isopropyl alcohol	phase 3	Antiseptic/disinfectant		Infection prevention/Dermatology

Therapeutic area mix

Diabetes · 1
Infection prevention/Dermatology · 1
Infectious Disease / Antisepsis · 1
Infectious Disease / Oral Health · 1
Oral Health / Dentistry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Federal University of Minas Gerais · 1 shared drug class
HaEmek Medical Center, Israel · 1 shared drug class
Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
Johns Hopkins University · 1 shared drug class
Norwegian University of Science and Technology · 1 shared drug class
The Cooper Health System · 1 shared drug class
Universidade Federal do Ceara · 1 shared drug class
University of Milan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad de Guanajuato:

Cite this brief

Drug Landscape (2026). Universidad de Guanajuato — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-de-guanajuato. Accessed 2026-05-17.